AbbVie Inc.

ABBV

US00287Y1091

Pharmaceuticals

Market Closed - Nyse Other stock markets 16:02:29 2024-06-28 EDT			5-day change	1st Jan Change
171.5 ^USD	+1.50%		+0.66%	+10.68%

06-28	Genmab, AbbVie's Lymphoma Therapy Recommended for Approval in EU	MT
06-28	AbbVie, Genmab Receive Positive European Opinion on Marketing Authorization for Possible Lymphoma Treatment	MT

AbbVie to Present at the Wolfe Research Healthcare Conference

November 09, 2022 at 08:01 am

NORTH CHICAGO, Ill., Nov. 9, 2022 /PRNewswire/ -- AbbVie (NYSE: ABBV) will participate in the 4^th Annual Wolfe Research Healthcare Conference on Tuesday, November 15, 2022. Rob Michael, vice chairman and president, Jeffrey R. Stewart, executive vice president, commercial operations, Scott Reents, senior vice president and chief financial officer, and Neil Gallagher, vice president development and chief medical officer will present virtually at 10:30 a.m. Central time.

A live audio webcast of the presentation will be accessible through AbbVie's Investor Relations website at investors.abbvie.com. An archived edition of the session will be available later that day.

About AbbVie

AbbVie's mission is to discover and deliver innovative medicines that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key therapeutic areas: immunology, oncology, neuroscience, eye care, virology, and women's health, in addition to products and services across our Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at www.abbvie.com. Follow @abbvie on Twitter, Facebook, Instagram, YouTube and LinkedIn.

View original content:https://www.prnewswire.com/news-releases/abbvie-to-present-at-the-wolfe-research-healthcare-conference-301672371.html

SOURCE AbbVie

Latest news about AbbVie Inc.

Genmab, AbbVie's Lymphoma Therapy Recommended for Approval in EU	06-28	MT
AbbVie, Genmab Receive Positive European Opinion on Marketing Authorization for Possible Lymphoma Treatment	06-28	MT
AbbVie Receives Positive CHMP Opinion for Epcoritamab for the Treatment of Adults with Relapsed/Refractory Follicular Lymphoma	06-28	CI
Health Care Stocks Fall With Broad Market -- Health Care Roundup	06-27	DJ
Sector Update: Health Care Stocks Slipping Late Afternoon	06-27	MT
Sector Update: Health Care Stocks Decline in Afternoon Trading	06-27	MT
AbbVie: acquisition of Celsius for $250 million	06-27	CF
AbbVie Buys Celsius Therapeutics for $250 Million	06-27	DJ
AbbVie Buys Celsius Therapeutics for $250 million	06-27	MT
AbbVie Buys Celsius Therapeutics for $250 million	06-27	MT
AbbVie Acquires Celsius Therapeutics in $250 Million Cash Deal	06-27	MT
Nxera Pharma Co Achieves Key R&D Milestone in Collaboration with AbbVie; Secures $10 Million Payment	06-27	MT
Nxera Pharma Co., Ltd. Receives USD 10 Million from AbbVie as Collaboration Targeting Neurological Diseases Achieves First R&D Milestone	06-26	CI
U.S. Food and Drug Administration Grants Second Approval for AbbVie's EPKINLY (epcoritamab-bysp) to Treat Patients with Relapsed or Refractory Follicular Lymphoma	06-26	CI
AbbVie Inc. acquired Celsius Therapeutics, Inc. for $250 million.	06-26	CI
AbbVie Gets New FDA Accelerated Approval for Epkinly	06-26	DJ
FDA Again Rejects AbbVie Parkinson's Drug/Pump Combo -- Update	06-25	DJ
AbbVie Issues Regulatory Update on New Drug Application for ABBV-951 to Treat Parkinson's Disease	06-25	MT
FDA Again Rejects AbbVie Parkinson's Drug/Pump Combo	06-25	DJ
US FDA declines to approve AbbVie's Parkinson's disease therapy	06-25	RE
AbbVie Provides U.S. Regulatory Update on ABBV-951 (Foscarbidopa/Foslevodopa)	06-25	CI
AbbVie Keeps Quarterly Dividend at $1.55 per Share, Payable Aug. 15 to Shareholders of Record July 15	06-21	MT
AbbVie Inc. Declares Quarterly Cash Dividend, Payable on August 15, 2024	06-21	CI
AbbVie Says Skyrizi Gets FDA Approval For Ulcerative Colitis	06-20	MT
US FDA proposes to remove switching study requirement for biosimilars	06-20	RE

Chart AbbVie Inc.

Duration

Period

More charts

Company Profile

AbbVie Inc. specializes in therapeutic drug research and development. Its products are intended for treating rheumatoid arthritis, psoriasis, Crohn's disease, thyroid disease, Parkinson's disease, HIV, complications of mucoviscidosis, low testosterone levels, and complications associated with chronic renal disease. Net sales are distributed geographically as follows: the United States (77.1%), Germany (2.3%), Canada (2%), Japan (1.9%), China (1.7%), France (1.4%), Spain ( 0.9%), Italy (0.9%), Australia (0.9%), Brazil (0.8%), United Kingdom (0.8%) and others (9.3%).

Sector

Pharmaceuticals

Calendar

2024-07-25 - Q2 2024 Earnings Release (Projected)

Related indices

S&P 500

More about the company

Income Statement Evolution

More financial data

Ratings for AbbVie Inc.

Trading Rating

Investor Rating

ESG Refinitiv

C+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

171.5 USD

Average target price

183.2 USD

Spread / Average Target

+6.83%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
ABBVIE INC.	+10.68%	303B
ELI LILLY AND COMPANY	+55.32%	815B
JOHNSON & JOHNSON	-6.75%	352B
MERCK & CO., INC.	+13.56%	314B
ASTRAZENECA PLC	+16.57%	242B
ROCHE HOLDING AG	+2.04%	224B
NOVARTIS AG	+13.31%	218B
AMGEN INC.	+8.48%	168B
PFIZER, INC.	-2.81%	159B
SANOFI	+0.20%	120B

Other Pharmaceuticals

AbbVie Inc.

Equities

ABBV

US00287Y1091

Pharmaceuticals

AbbVie to Present at the Wolfe Research Healthcare Conference

EPS Revisions